MECHANISM OF INCREASED PLASMA APO A1 LEVELS BY ESTROGENS

即使在控制了年龄影响后，绝经后女性患冠心病(CHD)的风险也比绝经前女性高。然而，雌激素替代疗法显著降低了绝经后女性患冠心病的风险。通过这项研究，我们建议在接受以下每种方案的安慰剂对照随机治疗的绝经后妇女中，确定载脂蛋白A-1的动力学，载脂蛋白A-1是高密度脂蛋白的主要蛋白质成分：a.安慰剂；b.0.625 mg/d结合雌激素；c.0.625 mg/d结合雌激素2.5 mg/d醋酸甲孕酮。载脂蛋白A-1的动力学将通过稳定同位素技术来确定。低剂量雌激素(B)和雌孕激素联合(C)是绝经后妇女常用的激素替代疗法，但存在代谢和载脂蛋白动力学问题。

Postmenopausal women are at higher risk of coronary heart disease (CHD) than premenopausal women, even after controlling for age-effects. However, estrogen replacement therapy significantly lowers the risk of CHD in postmenopausal women. With the study, we propose to determine the kinetics of apolipoprotein A-1, the major protein component of high density lipoproteins, in postmenopausal women undergoing a placebo-controlled, randomized treatment with each of the following regimens: a. placebo; b. 0.625mg/d conjugated estrogens; c. 0.625mg/d conjugated estrogens + 2.5 mg/d medroxyprogesterone acetate. The kineetics of apo A-1 will be determined by stable isotope techniques. The low dose estrogen (b) and the estrogen-progestin combination (c) are frequently prescribed to postmenopausal women as hormone replacement therapy, but there are metabolism and apolipoprotein kinetics.